BioSpace News Archive

Omeros receives $125 million in gross proceeds in sale of a portion of projected royalties receivable on net sales of OMIDRIA.

Beyond Air, Inc. today announced that the Annals of the American Thoracic Society published a detailed review of the Company’s third pilot study of inhaled NO in bronchiolitis patients.

Atsena Therapeutics announced positive results from the Phase I/II clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).

EMulate Therapeutics today announced the formation of a new technology advisory committee that will bring expertise across multiple disciplines to facilitate company growth and innovation.

PDS Biotechnology Corporation today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer.

Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Duke Heart validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients.

Codexis, Inc. today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors.

Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 (DNL151), as compared to placebo in approximately 400 participants with Parkinson’s disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene.

Ascendis Pharma A/S (Nasdaq: ASND) today announced completion of the dose-escalation portion and recommendation of the Phase 2 dose in transcendIT-101, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab.